Treatment News : ‘Test-And-Treat’ Would Slow HIV Spread, Improve Health Outcomes, but Raise Drug Resistance

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 25, 2013

‘Test-And-Treat’ Would Slow HIV Spread, Improve Health Outcomes, but Raise Drug Resistance

The public health policy of “test-and-treat”—testing widely for HIV and treating people immediately regardless of health status—would lower HIV transmission, AIDS and death rates, but double the rate of multidrug resistance (MDR) to antiretrovirals, according to a mathematical projection concerning men who have sex with men (MSM) in Los Angeles County (LAC). Researchers from the University of Southern California (USC) looked at the MSM population in LAC, analyzing HIV treatment methods and how they affected the virus between 2000 and 2009. They presented their projections in the advanced online edition of Clinical Infectious Diseases.

Using a deterministic epidemiological model to simulate the next decade of the epidemic among the LAC MSM population, the investigators compared the status quo to the potential implementation of a test-and-treat policy. They found that, by 2023, test-and-treat would lower new infections by 34 percent, deaths by 19 percent and new AIDS cases by 39 percent. At the same time, MDR would increase from the current 4.79 percent to 9.06 percent.

“We’re not saying that testing everybody and treating everybody is bad,” said the study’s principal investigator, Neeraj Sood, PhD, associate professor at the USC Schaeffer Center for Health Policy and Economics, in a release. “All we’re saying is that you should proceed with caution and closely monitor the prevalence of multidrug-resistant HIV as you scale up the test-and-treat model.”

To read the study abstract, click here.

To read a release on the study, click here.

Search: HIV, test-and-treat, AIDS, death rate, multidrug resistance, MDR, Los Angeles County, men who have sex with men, MSM, Neeraj Sood, University of Southern California.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    Sloan1
    Dallas
    Texas


    pevans
    San Francisco
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.